Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and Disease

健康和疾病中对 SARS-CoV-2 做出反应的保护性和致病性 T 细胞

基本信息

  • 批准号:
    10218954
  • 负责人:
  • 金额:
    $ 24.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-13 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

SUMMARY Understanding the adaptive response to SARS-CoV-2 is critical to halting the devastation wreaked by the COVID-19 pandemic, by identifying new drug targets and informing the rational design of vaccines. Common coronaviruses and human rhinovirus (RV) both cause common cold, and multiple strains of each exist that have varying degrees of sequence identity. All humans, and adults in particular, possess antigen-experienced immune cells by virtue of frequent viral infections. Our work using experimental infections with RV in man has provided unprecedented insight into adaptive immunity to this relatively benign, but troublesome, virus. Seminal findings include a pivotal role for the rapid mobilization of cross-reactive memory T helper 1 (Th1) cells and T-bet+ B cells in controlling RV infection. Th1 cells are critical to anti-viral responses by aiding in viral clearance through secretion of IFN-γ, and providing help to B cells for the production of neutralizing antibodies. Notably, expansion of circulating RV-specific Th1 cells is limited to those infected patients who develop serum neutralizing antibodies, whereas this feature is lacking in those who are infected but fail to mount an antibody response. Nonetheless, there is also evidence of a pathogenic role for virus-specific Th1 cells in patients with asthma who are at risk of adverse sequelae, based on enhanced and persistent responses. We posit that a similar scenario underlies the “cytokine storm” and rapid decline in patients with severe COVID-19 and those who are at risk, thereby reflecting the double-edged sword of Th1 cells in anti-viral immunity. The technological tools and analytical pipelines developed to study cross-strain immunity to RV infections, coupled with access to COVID-19 patients and those at risk, allow us to pivot quickly to analyze T cell responses to SARS-CoV-2. Powerful single-cell analytical tools for interrogating large cell numbers will be used to test the theory that cross-reactive T cells respond rapidly to SARS-CoV-2, and their numbers and functional attributes determine disease status in healthy individuals and at-risk patients. Based on our expertise, we are uniquely poised to map CD4+ T cell epitopes across the SARS-CoV-2 proteome. These data will be used to generate MHCII/peptide tetramers to detect and phenotype cross-reactive SARS-CoV-2-specific memory CD4+ T cells that pre-exist in uninfected adults and persist in recovered COVID-19 patients. This will establish proof-of- concept for priming of T cells for rapid response by previous exposures to related coronavirus strains (Aim 1). Next, novel computational tools and tetramers will be used to identify hallmarks of overactive virus-specific T cells in hospitalized COVID-19 patients in the acute phase, and to assess immune paralysis and antibody deficiencies in those who develop respiratory failure (Aim 2). Finally, we will confirm in vivo expansion of virus- specific pathogenic Th1 cells in uninfected asthmatics with severe disease, and boosting of their function by pro-inflammatory cues present in the lower airways (Aim 3). Study outcomes will yield new insight into T cell mechanisms of viral pathogenesis, and aid in vaccine design and monitoring for COVID-19.
总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Judith A Woodfolk其他文献

Use of a novel air cleaner to monitor airborne allergen
  • DOI:
    10.1016/s0091-6749(02)81248-9
  • 发表时间:
    2002-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Natalie J Custis;Judith A Woodfolk;John W Vaughan;Thomas AE Platts-Mills
  • 通讯作者:
    Thomas AE Platts-Mills

Judith A Woodfolk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Judith A Woodfolk', 18)}}的其他基金

Immune Programs and Related T Cell Mechanisms of Pulmonary Complications After COVID-19 Illness
COVID-19 疾病后肺部并发症的免疫程序和相关 T 细胞机制
  • 批准号:
    10886167
  • 财政年份:
    2023
  • 资助金额:
    $ 24.23万
  • 项目类别:
Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and Disease
健康和疾病中对 SARS-CoV-2 做出反应的保护性和致病性 T 细胞
  • 批准号:
    10488185
  • 财政年份:
    2021
  • 资助金额:
    $ 24.23万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8651423
  • 财政年份:
    2011
  • 资助金额:
    $ 24.23万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8106840
  • 财政年份:
    2011
  • 资助金额:
    $ 24.23万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8460063
  • 财政年份:
    2011
  • 资助金额:
    $ 24.23万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8244445
  • 财政年份:
    2011
  • 资助金额:
    $ 24.23万
  • 项目类别:
ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE
特应性皮炎:皮肤和免疫对减少过敏原暴露的反应
  • 批准号:
    8167150
  • 财政年份:
    2010
  • 资助金额:
    $ 24.23万
  • 项目类别:
ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE
特应性皮炎:皮肤和免疫对减少过敏原暴露的反应
  • 批准号:
    7951462
  • 财政年份:
    2009
  • 资助金额:
    $ 24.23万
  • 项目类别:
ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE
特应性皮炎:皮肤和免疫对减少过敏原暴露的反应
  • 批准号:
    7718542
  • 财政年份:
    2008
  • 资助金额:
    $ 24.23万
  • 项目类别:
ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE
特应性皮炎:皮肤和免疫对减少过敏原暴露的反应
  • 批准号:
    7606686
  • 财政年份:
    2007
  • 资助金额:
    $ 24.23万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 24.23万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了